Sephton also raised concerns over the mother’s right to privacy, adding: “The claimant says that it can only prove fraud if they have the telephone details, and yet the telephone details may prove to be entirely benign.
“However, they may contain, as I discussed in argument earlier on, matters which are private to [the policy holder's mother] which may be embarrassing to her.”
At the Court of Appeal hearing last week, Lord Justice Baker agreed, dismissing the appeal after calling EUI’s argument “misconceived.”
“It is true that the phone records may assist in establishing the truth of the parents' whereabouts. But in that regard the phone company is manifestly a mere witness,” Baker said.
“Its position is no different from anyone else who may be able to provide evidence about that issue,” he added.
Andrew Herring, fraud expert at Pinsent Masons, said the Court of Appeal’s decision highlighted the need for victims of fraud to “carefully consider their investigations of wrongdoing and fraud before launching Norwich Pharmacal applications.”
“Fraudsters are always innovating and one of the great strengths of the English common law is its flexibility to enable fraud victims to obtain effective relief,” he said. “The power to order Norwich Pharmacal relief is expansive and the courts are open to extending its use to help victims right a wrong in novel situations.”
“However, because Norwich Pharmacal relief is such a powerful tool in the litigator’s armoury, the courts naturally adopt a cautious approach,” Herring added.
“This case is an example of the courts being unwilling to accept the insurer applicant’s ‘ingenious argument’, and it illustrates the need for victims to carefully consider their investigations of wrongdoing and fraud before launching Norwich Pharmacal applications,” he said.
“In this case, the application failed on a number of grounds, including overriding human rights concerns, the fact that the mobile phone company was not engaged in the wrong and the availability of alternative routes to obtain evidence of fraud,” he said.
Herring added that, while the decision did not “close the door” on future Norwich Pharmacal relief against telecommunication companies, “it is a cautionary reminder of the need to ensure that any such applications do meet the relevant legal tests, which were fully upheld in this Court of Appeal decision. Had the use of mobile phones been an essential component of the fraud, the court might well have reached a different conclusion.”